Ian Chau

Active 2002–2025

162
Papers
41,474
Citations
81
h-index
155
i10-index

Citations

Citations per year for Ian Chau1979: 1 citations1991: 1 citations1994: 2 citations1996: 1 citations1998: 1 citations1999: 2 citations2001: 1 citations2002: 2 citations2003: 3 citations2004: 16 citations2005: 94 citations2006: 119 citations2007: 143 citations2008: 131 citations2009: 141 citations2010: 148 citations2011: 134 citations2012: 112 citations2013: 121 citations2014: 157 citations2015: 157 citations2016: 245 citations2017: 329 citations2018: 333 citations2019: 1,458 citations2020: 1,914 citations2021: 1,813 citations2022: 1,639 citations2023: 1,367 citations2024: 2,109 citations2025: 965 citations2026: 18 citations1980–1990: no citations, so these years are not shown1992–1993: no citations, so these years are not shown1995: no citations, so this year is not shown1997: no citations, so this year is not shown2000: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,288 citing papers, 21.7% of this breakdownChina: 2,720 citing papers, 13.8% of this breakdownItaly: 1,342 citing papers, 6.8% of this breakdownUnited Kingdom: 1,167 citing papers, 5.9% of this breakdownGermany: 1,061 citing papers, 5.4% of this breakdownJapan: 971 citing papers, 4.9% of this breakdownFrance: 901 citing papers, 4.5% of this breakdownSpain: 733 citing papers, 3.7% of this breakdownNetherlands: 628 citing papers, 3.2% of this breakdownCanada: 549 citing papers, 2.8% of this breakdownSouth Korea: 489 citing papers, 2.5% of this breakdownSwitzerland: 436 citing papers, 2.2% of this breakdown
0%21.7%Other 22.6%

Fields

  • Medicine79.4%
  • Biochemistry, Genetics and Molecular Biology14.1%
  • Immunology and Microbiology2%
  • Engineering1.7%
  • Mathematics0.4%
  • Neuroscience0.4%
  • Other2%

Topics

  • Cancer Immunotherapy and Biomarkers9.1%
  • Colorectal Cancer Treatments and Studies5.1%
  • Hepatocellular Carcinoma Treatment and Prognosis3.7%
  • Cancer Genomics and Diagnostics3.4%
  • Pancreatic and Hepatic Oncology Research3.2%
  • Gastric Cancer Management and Outcomes3.1%
  • Other72.4%

Coauthors

All papers

Open in search
  1. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pauline Funchain, Kathryn Bollin - Journal of Clinical Oncology 2021 cited by 1,964

  2. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mitch Dowsett, Johann S. de Bono, Paul Workman, Anguraj Sadanandam, Matteo Fassan, Owen J. Sansom, Suzanne A. Eccles, Naureen Starling, Chiara Braconi, Andrea Sottoriva, Simon P. Robinson, David Cunningham, Nicola Valeri - Science 2018 cited by 2,131

  3. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2018 cited by 3,697

  4. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2022 cited by 1,181

  5. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Doki, Yuichiro, Ajani, Jaffer A., Kato, Ken, Xu, Jianming, Wyrwicz, Lucjan, Motoyama, Satoru, Ogata, Takashi, Kawakami, Hisato, Hsu, Chih Hung, Adenis, Antoine, Di Bartolomeo, Maria, Braghiroli, Maria I., Holtved, Eva, Ostoich, Sandra A., Kim, Hye R., Ueno, Masaki, Mansoor, Wasat, Yang, Wen Chi, Liu, Tianshu, Bridgewater, John, Makino, Tomoki, Xynos, Ioannis, Liu, Xuan, Lei, Ming, Kondo, Kaoru, Patel, Apurva, Gricar, Joseph, Chau, Ian, Kitagawa, Yuko - 2022 cited by 532

  6. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Authors: , , , , , , , , , , , , , , - Annals of Oncology 2018 cited by 1,070

  7. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kathryn Bollin, Monalisa Ghosh - Journal of Clinical Oncology 2021 cited by 376

  8. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

    Authors: , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2015 cited by 1,734

  9. Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials

    Authors: , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2021 cited by 443

  10. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study

    Authors: , , , , , , , , , , , , , , , - The Lancet Oncology 2023 cited by 242

  11. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2013 cited by 2,200

  12. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2016 cited by 1,254

  13. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

    Authors: , , , , , , , , , , , - New England Journal of Medicine 2004 cited by 5,049

  14. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines

    Authors: , , , , , , , , , , , , , , , , - Annals of Oncology 2021 cited by 458

  15. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

    Authors: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2018 cited by 631

  16. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis

    Authors: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2016 cited by 919

  17. Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sebastian Guettler, Katharina von Loga, Sheela Rao, David Watkins, Naureen Starling, Ian Chau, Anguraj Sadanandam, David Cunningham, Marco Gerlinger - Cancer Cell 2019 cited by 262

  18. MRI-Diagnosed Tumor Deposits and EMVI Status Have Superior Prognostic Accuracy to Current Clinical TNM Staging in Rectal Cancer

    Authors: , , , , , , , , , , - Annals of Surgery 2020 cited by 196

  19. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2015 cited by 845

  20. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Per Pfeiffer, Naotoshi Sugimoto, Judit Kocsis, Andràs Csilla, G. Bodoky, Georgina Garnica Jaliffe, Светлана Проценко, Ayman Madi, Elżbieta Wójcik, Baruch Brenner, Gunnar Folprecht, Tomasz Sarosiek, Katriina Peltola, Peter Bono, Hubert Ayala, Giuseppe Aprile, Cardellino Giovanni Gerardo, Fidel David Huitzil Melendez, Alfredo Falcone, Francesco Di Costanzo, Moustapha Tehfe, Laurent Mineur, Pilar Alfonso, Radka Obermannová, Hélène Senellart, Russell Petty, Leslie Samuel, Péter Ács, Maen Hussein, M. Nechaeva, Frans Erdkamp, Elizabeth Won, Johanna C. Bendell, Javier Gállego, Sylvie Lorenzen, Bohuslav Melichar, Miguel Angel Escudero, Denis Pezet, Jean–Marc Phelip, Diego Kaen, James A. Reeves, Federico Longo Muñoz, Srinivasan Madhusudan, Carlo Barone, Luis Fein, Ángel Gómez Villanueva, Mohamed Hebbar, Jana Prausová, L. Visa Turmo, J. Vidal Barrull, Mette Yilmaz, Alex Beny, Hanneke W.M. van Laarhoven, Brian DiCarlo, Taito Esaki, Kazumasa Fujitani, Karen Geboes, Ravit Geva, Shigenori Kadowaki, Stephen Leong, Nozomu Machida, Moses S. Raj, Francisco Javier Ramírez Godinez, Ágnes Ruzsa, Hugo Ford, William Lawler, Nicolas Robert Maisey, Jiřı́ Petera, Einat Shacham‐Shmueli, Isabelle Sinapi and 44 more - The Lancet Oncology 2019 cited by 284

  21. BRAF Inhibition in BRAF V600 -Mutant Gliomas: Results From the VE-BASKET Study

    Authors: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2018 cited by 331

  22. Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial

    Authors: , , , , , , , , , , , , , , , , , , , - Gastric Cancer 2021 cited by 166

  23. Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis

    Authors: , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2017 cited by 405

  24. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

    Authors: , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2019 cited by 275